Objective: To determine if apneic preterm infants currently treated with methylxanthines develop evidence of sleep deprivation from cumulative arousal and motor activational effects.
Introduction
Apnea of prematurity is a common problem in very low birth weight (BW) infants. 1, 2 Standard treatment is with high-dose methylxanthines, theophylline (1,3-dimethylxanthine) or caffeine (1,3,11-trimethylxanthine), for several days or weeks during and following weaning from mechanical ventilation. 3, 4 Methylxanthines effectively decrease CO 2 levels, increase O 2 consumption and improve respiratory drive in human and animal models. 5 Caffeine has a higher therapeutic ratio, is absorbed more efficiently, and desired blood levels are easier to maintain than theophylline. 6 However, both methylxanthines produce autonomic side effects in the neonate, such as tachycardia, as well as renal and CNS toxicity, neutrophil compromise and a myriad of adverse effects at higher doses. 7 In apnea of prematurity, methylxanthines are assumed to act by blockade of adenosine receptors, A 1 and A 2A which act through both peripheral and central effects. 8 The current study examined chronic methylxanthine exposure effects on sleep, arousal and motor activation in premature infants following extubation. Prematurity, and specifically the 30 to 40 weeks post-menstrual age (PMA), is a critical developmental window for sleep-wake state organization, and the emergence of sustained arousal capacity. [9] [10] [11] [12] Although two laboratories have failed to find effects of methylxanthines on sleep states in the premature, 13, 14 behavioral indices of waking and temporal properties of movement were not studied. Thoman et al. 12 found increased wake and decreased active sleep 8 weeks after cessation of theophylline treatment in preterm infants.
In human and animal adult models, caffeine promotes wakefulness, producing dose-dependent effects that are rate limiting, short term and exhibit rapid tolerance. Microperfusion of the basal forebrain with the non-selective adenosine antagonist, theophylline, increases wakefulness and decreases sleep propensity. 15 Two mechanisms of action for caffeine's wake-promoting effects are through basal forebrain cholinergic stimulation and reinforcing inhibition of sleep-promoting neurons in the hypothalamus.
The longer half-life and neurotoxicity risk of methylxanthines in neonates compared to adults, 7 led to the hypothesis that developing sleep and arousal systems may be adversely affected by high dose, chronic methylxanthine treatment. In the present study, we examined the hypothesis that apneic preterms exposed to chronic methylxanthines may express sleep and arousal dysregulation, and structural disruption of spontaneous movements measured with an actigraphic piezoelectric mattress.
We hypothesized that the activational effects of chronic methylxanthine exposure would be cumulative. Therefore, duration of exposure would stimulate arousals and movement activation incrementally over days, tonically disrupting sleep, promoting sleep debt and increasing arousal threshold. Second, we hypothesized that sleep-deprived infants would show a decrease in sleep-related body movements on the day of testing as found by Franco et al. 16 in which healthy infants who were sleep deprived experimentally showed increased arousal threshold and decreased body movements, as well as increased apneic events. To explore these hypotheses, states of sleep, wake and brief arousals, and the temporal properties of actigraphically derived movement and quiescence periods were compared in methylxanthine-treated and matched -untreated neonates.
Methods

Subjects
Clinically stable, extubated infants (N ¼ 47) between 28 and 38 weeks PMA, and residing in the intermediate care nursery of the NICU at Eastern Maine Medical Center, Bangor, ME, USA were examined during a 5 h nocturnal sleep study (2400 to 0500 hours). Exclusionary criteria were neurological risks (intraventricular hemorrhage >grade II, intrauterine growth retardation, surgery or unusual medical course). Of the original sample, the data from eight infants were discarded based on complex pharmacological histories, one from post-test diagnosis of necrotizing enterocolitis, and one from a grade IV hemorrhage within 24 h of the sleep recording. None of the infants were small for gestational age (Table 1) .
Group characteristics
Three groups based on methylxanthine exposure immediately prior to the sleep study were determined: theophylline group (n ¼ 13), treated exclusively with either theophylline per os (p.o.) or aminophylline intravenously (i.v.) for X5 days; caffeine group (n ¼ 14) treated exclusively with caffeine p.o. for X5 days; and untreated control group (n ¼ 10) who had no history of theophylline, aminophylline or caffeine since birth.
Institutional Review Board approval and parental consent were obtained for the study, and infants were scheduled for testing. Infant participants were stabilized post-extubation (>24 h) in the intermediate care nursery of the NICU in standard isolettes. The sleep study was scheduled after determining that there were no significant health status changes in recent days. On the day of testing, blood level titer of methylxanthines was determined by heel stick using standard clinical mass spectroscopy.
Testing protocol
Infants were recorded in their home incubators and were dressed in a cotton undershirt and diaper. The incubator temperature was thermoneutral between 28 and 32 1C dependent upon infant skin temperature. Night-time light emanated from a low-level source below the incubators, and through natural light during the daytime, to allow for circadian light variation. Recording equipment was set-up in the early evening and recording was activated at 2400 hours following the 2300-hour feeding and vital signs nursing intervention. Nurses were requested to perform any significant care procedures in the evening before the 5 h recording. A second feeding occurred between 0300 and 0400 hours. Nursing interventions were brief to maximize undisturbed, spontaneous sleep-wake alternations. 17 Recordings. All infants were maintained in the supine sleep position throughout the 5-h nocturnal recordings. Phase-locked videographic and actigraphic recordings between 2400 and 0500 hours were conducted in the infant's usual isolette. Spontaneous movements were quantified by actigraphy using a 10 Â 10 Â 1 mm piezoelectric sensor placed beneath the infant's body, centered at the scapula, and reaching from the lower head to the buttocks. Calibrated, analog signals from movements including respirations were sampled and digitized at a rate of 4 s À1 and stored by a microcomputer. Analysis of the overall level and the temporal structure of spontaneous movements and quiescence periods are described below. Phase-locked infrared, time-lapse videosomnography was recorded to determine behavioral state, and the qualitative character of movements for comparison to the electronically sensed movement data.
State coding. Behavioral categories for coding behavioral sleep states were based on the criteria from earlier developmental sleep-wake state studies of premature infants. 18, 19 These criteria are summarized in Table 2 . For state determination, a 3-min epoch size was adopted. Criteria for each state must be met consecutively for a minimum of 1.5 min of each 3-min bin. This method uses longer epochs than 1 min criterion used in some studies and is based on the Anders et al. 20 technique, which corrects for state transitions and transient states which are a particular problem in state coding of premature infants. 19 As described in Table 2 , the distinction between an arousal vs wake state is time based. Brief arousals are frequent in premature infants of this age. They were defined as 'brief' if the criterion duration of 1 to 1.5 min was reached. Durations above 1.5 min met the duration criterion for wake state. A wake composite index was derived from the sum of the exclusive categories based on the frequency of wake state epochs and brief arousals. This wake composite index quantifies the total incidence of separate waking events across the 5 h recording.
Data analysis
State variables were coded as percent, epoch duration, epoch number, number of state transitions and total sleep time. Five-hour video recordings were coded by multiple, independent observers unaware of group membership or the hypotheses of the study. Kappa coefficients were determined for inter-rater reliability and ranged from 0.65 to 0.94. Methylxanthine blood titers and days of prior methylxanthine exposure were analyzed with regression procedures for all state and movement parameters. One-way analysis of variance was used to examine parameter changes for treatment group with GA and number of days on medication prior to testing as covariates.
Actigraphy
The temporal structure of movement and quiescence bouts were determined as described in our previous work.
11 ,21 Bout structure refers to the distribution of movement in clusters. These bouts were analyzed consecutively. Movement and quiescence periods were calculated based on the infant's actigraphic output across the 5 h period. Nursing intervention/ feeding periods (<20 min) were determined by videography, and the actigraphic data were excluded from analysis. A modified time-above-threshold method was used with each infant's average movement output used as the threshold above which movement (1) or quiescence (0) was coded iteratively based on epoch lengths. The criterion for bout onset was two consecutive epoch values above the session mean (sequence: 1,1), and bout termination was two consecutive bin averages below the session mean (sequence: 0,0). This analysis yielded a measure of the number, average duration and maximum duration of movement bouts during the recording. Similarly, bout analysis was conducted with quiescence bouts using sequence (0,0) for bout onset, and (1,1) for bout termination.
The analysis of bout structure was conducted using lenses of different epoch length (12 s, 60 s and 6 min). For example, a micro-analytic approach allowed for characterizing brief events such as motor burst or pauses by organizing the data into 12-s bins. The 12 s category reflects local, continuous behavioral activity or quiescence over a relatively brief window, and therefore, reflects the rapid alternations between movement and quiescent periods. This captures the temporal organization of motor bursts that was found in our previous work to be most characteristic of premature infant spontaneous movements. The 60 s bin size averages across a wider temporal window. This approach corrects for brief pauses in ongoing motor or quiescent periods to characterize minute-to-minute variation. The 6-min bin size category averages across a broad time interval, which is reflective of 'state-like' organization at this developmental age. To examine the role of cumulative effects, we conducted regression analyses using exposure duration (that is, number of days) as the predictor variable based on the lifetime history of methylxanthine exposure in days. Theophylline and caffeine groups were examined separately. As described in the Methods section, theophylline group had prior exposure to theophylline p.o. or aminophylline i.v. exclusively. The mean days of prior exposure was 12.8 (s.d. ¼ 6.36; range ¼ 5 to 25). In contrast, caffeine group had caffeine only for >5 days prior to testing, but most infants (11/14) had had prior exposure to theophylline or aminophylline which is the standard of care for this nursery (mean days on caffeine ¼ 16.2, s.d. ¼ 11.42). Importantly, the mean duration of any prior methylxanthine exposure was significantly longer in the caffeine than the theophylline group (mean ¼ 27.6, s.d. ¼ 13.84; range ¼ 5 to 45 days, t(26) ¼ 3.61; P<0.001).
Duration and state parameters
As shown in Table 3 , no relationship was found for methylxanthine duration and sleep or arousal parameters for the theophylline group, although the caffeine group's slope was positive, and values increased for arousal indices: wake epochs, % wake state and composite wake index events. The wake composite index measure was derived from the sum of discrete wake state epochs and brief arousals, and quantifies the incidence of separate waking events across the 5 h recording. Caffeine group showed a significant decline in active sleep with duration of exposure.
Duration and sleep-related actigraphic movements
The actigraphy data were gathered using a piezoelectric mattress device. We analyzed sleep-related spontaneous movements by first removing from the analyses actigraphy data during wake-arousal events by examining the phase-locked videographic record. Next, sleep-related movement and quiescence bouts were examined separately. All of the data were binned into short (12 s), moderate (60 s) and long or state-like (6 min) epochs to examine the temporal properties of sleep-related motility and quiescence bouts (see Methods section). Bout duration mean, maximum length across the recording and bout number were calculated using algorithms developed in our laboratory. 11, 21 As shown in Table 3 , methylxanthine exposure was associated with an increase in the maximum movement bout duration for 60 s epochs for both theophylline and caffeine; while 60 s epoch analyses yielded longer mean bout duration and maximum bout duration for 12 s epochs for caffeine only. Mean movement bout duration in 6 min epochs increased with days of exposure to theophylline.
Developmental changes in state or movement and quiescence temporal segregation, for example, characteristically longer duration bouts with age, 11 were examined by Pearson's correlations of GA, PMA and days of prior methylxanthine exposure for each group. As expected, PMA correlated significantly with days of prior methylxanthine exposure (theophylline: r(13) ¼ 0.93, P<0.001; caffeine group: r(14) ¼ 0.73, P<0.01; collapsing across both groups: r(27) ¼ 0.84, P<0.001). Hence, infant age could be compounding the observed actigraphy changes attributed to exposure. To address this, we redid the analyses, using a stepwise regression entering PMA first, followed by duration of prior exposure for each group. For the caffeine group, the model was not improved for state. Maximum motility bout (60 s epochs) increased with exposure duration, as was found previously (overall F(2,12) ¼ 11.6, P<0.003; exposure: P<0.001). Mean bout duration decreased with postnatal age (P<0.04). For the theophylline group, there was no change in the results by adding postnatal age in either the state or motor activity measures.
Group differences
A one-way analysis of variance was applied adding GA and methylxanthine exposure duration as covariates. As shown in Figure 1 , statistically significant group differences were found for all arousal and wake measures based on methylxanthine treatment status. The model produced a main effect for group (F(4,31) ¼ 5.91; P<0.007) for percent wake state (F(2,31) ¼ 3.55; P<0.02). Post hoc analyses showed that theophylline group showed significantly less wake (P<0.005) when contrasted with the untreated group, and the caffeine group trended in the same direction. The frequency of wake epochs was significant in the model (F(4,31) ¼ 3.09; P<0.03), with a main effect for treatment group (F(2,31) ¼ 5.95; P<0.006); post hoc analyses revealed that both theophylline (P<0.007) and caffeine (P<0.02) groups had significantly fewer wake epochs than the untreated group. Brief arousals were significantly different (F(4,31) ¼ 2.9; P<0.04), showing a main effect of group (F(2,31) ¼ 3.2; P<0.03), and were less frequent in the theophylline group (P<0.03), but not the caffeine group, when contrasted with the untreated group. For composite wake index, the model was significant (F(4,31) ¼ 3.7; P<0.01), with a main effect for group (F(2,31) ¼ 6.4; P<0.005); both theophylline (mean ¼ 3.6; s.d. 
Movement analyses
As described in the Methods section, brief arousals and awakenings, as well as nursing interventions, were converted into missing to detect sleep-related motility changes independent of wake events. To detect group effects, the same model was applied: a one-way analysis of variance, using GA and duration of methylxanthine exposure as covariates. In Figure 2 , the 12-s epoch window showed a main effect for group (F(2,31) ¼ 5.74, P<0.008) and bout duration. Post hoc analyses revealed significantly lower sleep-related bout duration for theophylline (P<0.003) and Figure 1 Mean (s.d.) for wake state %; number of discrete wake epochs; brief arousals and composite wake index in a 5 h sleep and actigraphy recording (2400 to 0500 hours) in premature infants (29 to 38 PCA). Theophylline group differed significantly from untreated group on all measures; caffeine group differed significantly from untreated group in wake epochs and composite wake index. *Pp0.05; **P<0.01.
caffeine (P<0.009) groups compared to the untreated group, but treated groups were not different. Similarly, Figure 3 maximum bout duration was lower in the treated groups (F(2,31) ¼ 3.35, P<0.05; theophylline: P<0.05; caffeine: P<0.02). As shown in Figure 4 , the 60-s epoch window revealed that maximum sleeprelated movement was significantly shorter in treated groups than the untreated group (F(2,31) ¼ 3.53, P<0.04; theophylline: NS; caffeine P<0.01). For both short (60 s) and long (6 m) epoch windows, low motility or quiescence bout maxima across the 5 h session were shorter for theophylline, although only 6 m was significantly different from untreated group for caffeine (60 s epochs: (F(4,31) ¼ 3.5, P<0.045; Post hoc for theophylline: P<0.014; caffeine: NS; 6 m epochs: (F(4,31) ¼ 6.24, P<0.005; theophylline: P<0.004, caffeine: P<0.05).
Discussion
Premature neonates with apnea are generally maintained on high doses of methylxanthines for long periods to achieve therapeutic efficacy. The findings of our study suggest that the standard regimens of caffeine and theophylline, even when carefully titrated to achieve therapeutic levels, are associated with cumulative activational effects. On the night of testing, methylxanthine groups had lower arousal rates and suppressed duration of sleep-related spontaneous movements compared to untreated infants. Methylxanthine group differences on the night of testing, using cumulative exposure duration and GA as covariates, revealed that theophylline and caffeine groups exhibited less wakefulness than untreated infants according to % wake state, number of brief arousals (>1 m), sustained awakenings (number of wake state epochs >1.5 m) and lower composite arousal index scores.
The period of 28 to 38 weeks PMA is a developmental window in which neurobehavioral systems (for example, state and spontaneous movements), transition from a poorly differentiated fetal pattern to a more organized neonatal state organization characterized by state stability, and in particular, sustained and predictable wakefulness periods. Untreated premature infants of this age, in contrast to term-aged infants, are most likely to be awake between 0200 and 0500 hours. 22 Whether sustained, high-dose methylxanthine treatment in preterm infants is associated with long-term functional changes in neonatal arousal systems is not well studied.
The unfortunate difficulties of analyzing complex drug effects in the human neonate is most challenged when treatment is clinically, rather than experimentally, determined. Nonetheless, few neonatal studies have contrasted acute, chronic and/or post-treatment effects. In the present study, duration of methylxanthine exposure was associated with a linear increase in waking and motor parameters, particularly for the longer treated caffeine group, and hence this factor was covaried in the group analyses which found reduced arousals and waking state. From an explanatory perspective, the decrease in behavioral arousals in the methylxanthine groups could be mediated by two factors: maturational status and/or sleep deprivation.
With regard to maturation, the caffeine and theophylline groups differed in both drug exposure history and GA, and the caffeine group was different from both other groups in BW. In contrast the comparison group, although similar in PMA at time of testing and other demographics, had an unremarkable postnatal course, hence, ex utero development and neuroplasticity may be responsible for some of the observed differences from the methylxanthine-exposed infants.
The second hypothesis is that premature infants treated with methylxanthines for prolonged periods may show fewer arousals from accumulated sleep debt secondary to the stimulatory effects of chronic methylxanthine exposure, a finding that has been reported in adults. 23 In a well-controlled study by Curzi-Dascolova et al. 13 no sleep or arousal effects were found after >3 days of caffeine treatment. However, long-term methylxanthine treatment in our study promoted sleep fragmentation, as reflected in both state and actigraphic results, and lowered arousal parameters including the vigor of spontaneous movements during sleep. Movement suppression during sleep and increased apneic events has been reported recently in experimentally sleep-deprived, normal infants, 16 and is consistent with earlier reports of arousal suppression associated with sleep deprivation. 24, 25 Nonetheless, developmental neurotoxic sequelae from early methylxanthine pharmacotherapy in sleep-wake state properties has not been well studied. In neonatal rabbits, one dose (10 mg kg À1 ) of theophylline on postnatal day 1 led to 3 weeks of increased waking, decreased active sleep and delay of quiet sleep development. 26 Similarly, Thoman et al. 12 reported that infants previously treated with theophylline, but not currently treated, showed higher rates of wake and drowse/transitional states when examined in the home.
Future work is needed to determine the parameters of methylxanthine exposure duration that may signal risk for potentially deleterious effects on the premature. 12, 24 The potential long-term effects of neonatal methylxanthine treatment on CNS processes controlling sleep and arousal organization require further study.
